Table 4.

Summary of published clinical mouthrinse efficacy studies used for comparison with in vitro results

Clinical scorea				Concn (%)	No. of subjects	Duration (days)	Endpoint(s)b	RPIc	Reference
CHX	CPC	SLS	TRN
2				0.2	15	4	PI, PA	0.50	21
		1		0.25				0.920.96
			0	0.06
		1		1.5	11	4	PI	0.49	37
			0	0.3				0.33
			0	0.15				0.35
2				0.05	20	4	PI, PA	0.80	9
	2			0.1				0.75
	2			0.05				0.81
			1	0.05				0.94
2				0.01	26	4	PI, PA	0.89	10
2				0.05				0.67
2				0.1				0.64
2				0.2				0.55
			1	0.2				0.93
2				0.2	12	4	PI	0.11	12
			1	0.3				0.23
			1	0.15				0.52
			1	0.075				0.58
2				0.12	20	4	PI, PA	0.63	27
	1			0.05				0.83
			1	0.03				0.86
2				0.2	76	35	PI, BOP, MGI	0.00	42
	1			0.05				0.47
			1	0.3				0.61
2				0.12	298	157	PI, GI	0.69	33
	1			0.1				0.81
	1			0.075				0.83
2				0.12	16	4	PI	0.88	39
			0	0.3				0.98
2				0.2	15	4	PI	0.35	23
2				0.12				0.46
	0			0.05				0.93
			1	0.03				0.77

^aSee Materials and Methods for an explanation of the clinical score.

^bPI, plaque index; PA, plaque area; BOP, bleeding on probing; MGI, modified gingival index; GI, gingival index; VAB, viable anaerobic bacteria.

^cRPI, relative plaque index. The RPI is the PI value measured for a treatment divided by the PI value of the corresponding control.